Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | ENO1 | P06733 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10378803 | 0.87 | ALDH1A1 (0.49) | TSHRALDH1A1CETPENO1PRKCA | |
| SCHEMBL21189481 | 0.87 | ALDH1A1 (0.49) | TSHRALDH1A1CETPENO1PRKCA | |
| SCHEMBL5615430 | 0.83 | TSHR (0.55) | TSHRALDH1A1CETPSRCFOLH1 | |
| SCHEMBL28720185 | 0.81 | BTN3A1 (0.53) | ALDH1A1ENO1PRKCABTN3A1ELANE | |
| SCHEMBL3437081 | 0.81 | BTN3A1 (0.53) | ALDH1A1ENO1PRKCABTN3A1ELANE | |
| SCHEMBL21446911 | 0.81 | TSHR (0.69) | TSHRALDH1A1CETPSRCFOLH1 | |
| SCHEMBL5615776 | 0.80 | TSHR (0.63) | TSHRALDH1A1CETPSRCFOLH1 | |
| SCHEMBL20701826 | 0.80 | TSHR (0.79) | TSHRALDH1A1CETPSRCFOLH1 | |
| SCHEMBL10378847 | 0.79 | BTN3A1 (0.51) | ALDH1A1ENO1PRKCABTN3A1ELANE | |
| SCHEMBL51316 | 0.79 | TSHR (1.00) | TSHRALDH1A1CETPSRCFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039872-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2016-02-11 | — | — | US | disclosed |
| WO-2014153101-A2 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039872-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PHKG1, ACP1 | TSHR 3105/4885ALDH1A1 4878/4885CETP 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.